Chlorine in PDB 6vbp: Crystal Structure of Anti-Hiv-1 Antibody DH815 Bound to GP120 V2 Peptide

The structure of Crystal Structure of Anti-Hiv-1 Antibody DH815 Bound to GP120 V2 Peptide, PDB code: 6vbp was solved by B.M.Janus, G.Ofek, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	45.15 / 2.30
Space group	P 1 21 1
Cell size a, b, c (Å), α, β, γ (°)	69.903, 158.531, 92.646, 90.00, 110.27, 90.00
R / Rfree (%)	18 / 22.9

The binding sites of Chlorine atom in the Crystal Structure of Anti-Hiv-1 Antibody DH815 Bound to GP120 V2 Peptide (pdb code 6vbp). This binding sites where shown within 5.0 Angstroms radius around Chlorine atom.
In total only one binding site of Chlorine was determined in the Crystal Structure of Anti-Hiv-1 Antibody DH815 Bound to GP120 V2 Peptide, PDB code: 6vbp:

Chlorine binding site 1 out of 1 in the Crystal Structure of Anti-Hiv-1 Antibody DH815 Bound to GP120 V2 Peptide


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 1 of Crystal Structure of Anti-Hiv-1 Antibody DH815 Bound to GP120 V2 Peptide within 5.0Å range: probe atom residue distance (Å) B Occ C:Cl301 b:59.1 occ:1.00 O C:HOH420 2.0 61.4 1.0 HD21 C:ASN204 2.6 86.1 1.0 HZ1 C:LYS201 3.1 0.9 1.0 HZ1 A:LYS12 3.1 96.6 1.0 ND2 C:ASN204 3.4 71.7 1.0 HD22 C:ASN199 3.4 69.9 1.0 HA C:ASN204 3.5 77.0 1.0 HG2 C:LYS201 3.5 88.6 1.0 HD22 C:ASN204 3.6 86.1 1.0 HE3 C:LYS206 3.7 79.1 1.0 OD1 C:ASN199 3.7 59.9 1.0 NZ C:LYS201 3.9 99.9 1.0 HZ1 C:LYS206 3.9 84.7 1.0 HE2 C:LYS206 3.9 79.1 1.0 HZ3 C:LYS201 3.9 0.9 1.0 NZ A:LYS12 4.0 80.5 1.0 HA C:LYS201 4.0 57.5 1.0 ND2 C:ASN199 4.1 58.2 1.0 CE C:LYS206 4.2 65.9 1.0 HZ2 C:LYS201 4.2 0.9 1.0 HZ2 A:LYS12 4.2 96.6 1.0 HD3 A:LYS12 4.3 86.2 1.0 CG C:ASN199 4.3 55.8 1.0 CA C:ASN204 4.4 64.1 1.0 HZ3 A:LYS12 4.4 96.6 1.0 HB3 C:ASN204 4.4 80.3 1.0 OE1 A:GLU10 4.5 77.5 1.0 CG C:ASN204 4.5 69.7 1.0 NZ C:LYS206 4.5 70.5 1.0 CG C:LYS201 4.5 73.8 1.0 HB2 C:LYS206 4.6 61.9 1.0 CB C:ASN204 4.7 66.9 1.0 C C:ASN204 4.8 66.3 1.0 HD21 C:ASN199 4.9 69.9 1.0 HG3 C:LYS201 4.9 88.6 1.0 CE A:LYS12 4.9 77.6 1.0 CA C:LYS201 5.0 47.9 1.0 HZ3 C:LYS206 5.0 84.7 1.0 CD A:LYS12 5.0 71.8 1.0

D.Easterhoff, J.Pollara, K.Luo, B.Janus, N.Gohain, L.D.Williams, M.Z.Tay, A.Monroe, K.Peachman, M.Choe, S.Min, P.Lusso, P.Zhang, E.P.Go, H.Desaire, M.Bonsignori, K.K.Hwang, C.Beck, M.Kakalis, R.J.O'connell, S.Vasan, J.H.Kim, N.L.Michael, J.L.Excler, M.L.Robb, S.Rerks-Ngarm, J.Kaewkungwal, P.Pitisuttithum, S.Nitayaphan, F.Sinangil, J.Tartaglia, S.Phogat, K.Wiehe, K.O.Saunders, D.C.Montefiori, G.D.Tomaras, M.A.Moody, J.Arthos, M.Rao, M.G.Joyce, G.A.Ofek, G.Ferrari, B.F.Haynes. Hiv Vaccine Delayed Boosting Increases Env Variable Region 2-Specific Antibody Effector Functions. Jci Insight V. 5 2020.
ISSN: ISSN 2379-3708
PubMed: 31996483
DOI: 10.1172/JCI.INSIGHT.131437